Michael J Birrer, MD, PhD

home / authors / michael-j-birrer-mdphd

Articles

Dr Birrer on Molecular Stratification in Endometrial Cancer

September 8th 2023

Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.

Key Data Highlights in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

November 17th 2022

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Treatment of Rare Tumors in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

November 17th 2022

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

Investigative Therapies in Recurrent Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

November 10th 2022

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

November 10th 2022

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Antibody-Drug Conjugates in Ovarian Cancer Treatment

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

November 4th 2022

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

November 4th 2022

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

PARP Inhibitor Resistance in Ovarian Cancer Treatment

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

October 27th 2022

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

October 27th 2022

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

October 20th 2022

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

October 20th 2022

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial

Bradley J. Monk, MD, FACS, FACOG;Robert L. Coleman, MD, FACOG, FACS;Shannon N. Westin, MD, MPH, FACOG;Michael J Birrer, MD, PhD

October 17th 2022

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.